Deutsche Bank Aktiengesellschaft Increases BioNTech (NASDAQ:BNTX) Price Target to $150.00

BioNTech (NASDAQ:BNTX) had its price objective lifted by Deutsche Bank Aktiengesellschaft from $95.00 to $150.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target indicates a potential upside of 33.59% from the stock’s previous close.

BNTX has been the subject of a number of other research reports. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. HSBC upgraded BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and increased their price target for the company from $96.00 to $150.00 in a research note on Tuesday. Bank of America upped their target price on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Finally, JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and raised their price target for the stock from $91.00 to $125.00 in a research report on Monday, September 16th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $124.54.

BioNTech Stock Performance

Shares of NASDAQ:BNTX opened at $112.28 on Thursday. The firm’s 50 day simple moving average is $90.26 and its 200 day simple moving average is $90.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The company has a market capitalization of $26.69 billion, a price-to-earnings ratio of 227.96 and a beta of 0.23. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter last year, the company earned ($0.86) earnings per share. The firm’s revenue was down 23.3% compared to the same quarter last year. As a group, sell-side analysts forecast that BioNTech will post -2.8 earnings per share for the current year.

Institutional Trading of BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Candriam S.C.A. grew its holdings in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares during the last quarter. Neuberger Berman Group LLC bought a new stake in BioNTech in the fourth quarter valued at approximately $1,562,000. US Bancorp DE increased its position in shares of BioNTech by 420.7% during the fourth quarter. US Bancorp DE now owns 28,614 shares of the company’s stock worth $3,020,000 after buying an additional 23,119 shares during the period. Goldman Sachs Group Inc. raised its position in shares of BioNTech by 17.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock worth $19,301,000 after acquiring an additional 26,777 shares in the last quarter. Finally, Harding Loevner LP acquired a new position in BioNTech in the fourth quarter valued at approximately $410,984,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.